Roche: new therapeutic indication for Tecentriq
(CercleFinance.com) - The US Food and Drug Administration has approved Roche's Tecentriq plus chemotherapy for the initial treatment of metastatic non-squamous non-small cell lung cancer, the Swiss drugmaker said on Wednesday.
In lung cancer, Tecentriq has been approved in the US in combination with Roche's Avastin and chemotherapy, for the initial treatment of adults with metastatic non-squamous non-small cell lung cancer, with no genomic tumour aberrations.
In the US, Roche's immunotherapy is also approved by the FDA to treat adults with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
In lung cancer, Tecentriq has been approved in the US in combination with Roche's Avastin and chemotherapy, for the initial treatment of adults with metastatic non-squamous non-small cell lung cancer, with no genomic tumour aberrations.
In the US, Roche's immunotherapy is also approved by the FDA to treat adults with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy.
Copyright (c) 2019 CercleFinance.com. All rights reserved.